Ardena’s customer Vicore Pharma initiates clinical trials with a new drug

Our customer Vicore Pharma Holding AB has recently announced the initiation of a first-in-human trial with C106, an orally available novel drug with target engagement and anti-fibrotic effects in human fibrotic lung and kidney tissue at clinically relevant concentrations.

At Ardena, we sincerely congratulate Vicore’s team on this important milestone. We are proud of our broad contribution to this project over time, encompassing both drug substance and drug product, as well as CMC regulatory writing, and look forward to continuing our successful collaboration with Vicore Pharma with C106 and other candidates.

Read more about Vicore’s announcement here: Press – Vicore Pharma